August 17, 2017August 17, 2017
Longer Treatment Could Help ANCA-Associated Vasculitis Patients Avoid Relapse, Study Finds
News
People with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have a lesser chance of relapse if they continue with maintenance ... Read more
August 4, 2017August 4, 2017
HemaCare Expands Portfolio of Disease State Cells for Biotech Research
News
HemaCare Corporation‘s recent expansion of its disease state materials portfolio includes serums from rare diseases such as granulomatosis with polyangiitis ... Read more
July 19, 2017July 19, 2017
Vasculitis Foundation’s 2017 Symposium Lures Doctors, Patients From Around the World to Chicago
News
Physicians, specialists, patients and families touched by vasculitis nationwide and around the world gathered June 23 at the Vasculitis ... Read more
July 14, 2017July 14, 2017
EC Approves MabThera Biosimilar Rixathon for Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
News
The European Commission (EC) has approved the use and marketing in Europe of Rixathon, a biosimilar to Roche’s MabThera (rituximab). ... Read more
July 11, 2017
Nucala Triggered Remission in Eosinophilic Granulomatosis with Polyangiitis, But Not All Benefit
News
Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or ... Read more
June 29, 2017June 29, 2017
Verona Gets Green Light to Enroll Patients in European Trial of COPD Therapy RPL554
News
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a ... Read more
June 27, 2017June 27, 2017
UK’s National Health Service Approves Daxas as Treatment for COPD
News
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, ... Read more
June 22, 2017June 22, 2017
$10M NIH Grant Aims to Identify Genes Linked to COPD, Other Diseases
News
The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the ... Read more

Longer Treatment Could Help ANCA-Associated Vasculitis Patients Avoid Relapse, Study Finds

People with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have a lesser chance of relapse if they continue with maintenance treatment for two years instead of one, according to the results ... Read more

August 4, 2017August 4, 2017

HemaCare Expands Portfolio of Disease State Cells for Biotech Research

News

HemaCare Corporation‘s recent expansion of its disease state materials portfolio includes serums from rare diseases such as granulomatosis with polyangiitis (GPA). The Los Angeles-based supplier of human blood and immune ... Read more

July 19, 2017July 19, 2017

Vasculitis Foundation’s 2017 Symposium Lures Doctors, Patients From Around the World to Chicago

News

Physicians, specialists, patients and families touched by vasculitis nationwide and around the world gathered June 23 at the Vasculitis Foundation’s 2017 International Vasculitis Symposium in Chicago. “Physicians and patients around ... Read more

July 14, 2017July 14, 2017

EC Approves MabThera Biosimilar Rixathon for Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

News

The European Commission (EC) has approved the use and marketing in Europe of Rixathon, a biosimilar to Roche’s MabThera (rituximab). The decision follows a positive review of Rixathon by the ... Read more

July 11, 2017

Nucala Triggered Remission in Eosinophilic Granulomatosis with Polyangiitis, But Not All Benefit

News

Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a ... Read more

June 29, 2017June 29, 2017

Verona Gets Green Light to Enroll Patients in European Trial of COPD Therapy RPL554

News

Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The ... Read more

June 27, 2017June 27, 2017

UK’s National Health Service Approves Daxas as Treatment for COPD

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could ... Read more

June 22, 2017June 22, 2017

$10M NIH Grant Aims to Identify Genes Linked to COPD, Other Diseases

News

The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the McDonnell Genome Institute at Washington University to investigate and identify ... Read more